Comparative Pharmacology
Head-to-head clinical analysis: MYOTONACHOL versus URECHOLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYOTONACHOL versus URECHOLINE.
MYOTONACHOL vs URECHOLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Myotonachol (bethanechol chloride) is a direct-acting parasympathomimetic agent that selectively stimulates muscarinic acetylcholine receptors, particularly M3 subtypes, in smooth muscle of the gastrointestinal tract and urinary bladder. It mimics the action of acetylcholine but is resistant to hydrolysis by acetylcholinesterase, leading to increased smooth muscle tone and peristalsis.
Bethanechol is a synthetic choline ester that directly stimulates muscarinic acetylcholine receptors, primarily M2 and M3 subtypes, leading to increased gastrointestinal motility, bladder contraction, and other parasympathetic effects. It has minimal nicotinic activity.
25 mg orally three times daily. Maximum dose 100 mg four times daily.
10-50 mg orally two to four times daily; alternatively, 5 mg subcutaneously three to four times daily. Maximum oral dose: 200 mg daily.
None Documented
None Documented
Terminal elimination half-life: 1.5-2.5 hours (prolonged in renal impairment).
Terminal elimination half-life is approximately 1.5-2 hours. Due to its short half-life, continuous or frequent dosing is required for sustained cholinergic effects.
Renal: 70-80% unchanged; biliary/fecal: 20-30% as metabolites.
Primarily renal excretion of unchanged drug and metabolites; approximately 50-60% excreted in urine within 24 hours, with negligible biliary or fecal elimination.
Category C
Category C
Cholinergic Agonist
Cholinergic Agonist